No Carolina / NY / Florida
Ph: 561.316.3330

Samsung Demonstrates Viability of Lower Dose Digital Radiography Algorithm for Pediatric Patients

Summation

  • “Findings of our clinical trial showed that use of Samsung's S-Vue™ for pediatric chest images resulted in an overall image quality that was uncompromised even at a significantly reduced radiation exposure,” said Susan John, MD, Professor and Chair, Diagnostic and Interventional Imaging at McGovern Medical School at The University of Texas Health Science Center at Houston (UT Health).
  • We are delighted that we are now able to offer this to the patients who are most vulnerable,” said David Legg, Vice President, Head of Ultrasound and Digital Radiography Business, at NeuroLogica, the healthcare subsidiary of Samsung Electronics.
  • “Constantly working to lower dose exposure is a top priority for radiologists and healthcare professionals, and Samsung's ability to offer dose reduction across its suite of DR machines represents another breakthrough in medical imaging technology.

Samsung announced that its new image post-processing engine (IPE), S-Vue™ 3.02, recently received FDA clearance. The technology employs an advanced noise-reduction algorithm that allows devices to produce the same high-quality image using a fraction of the radiation in pediatric patients. Image evaluations on devices using S-Vue™ showed they reduced X-ray dose up to 45% for pediatric abdomen exams, 15.5% for pediatric chest exams, and up to 27% for pediatric skull exams as compared with the previous IPE on the same X-ray systems. This data underscores Samsung’s commitment to minimizing dose exposure, especially in pediatric patients requiring repeated exposure.

Samsung’s digital radiography (DR) machines – including GC85A and GM85 – incorporate Samsung’s S-Vue™ 3.02, which provides spatially adaptive multi-scale processing and advanced de-noising technology, delivering quality images with a fraction of the dose.

“Findings of our clinical trial showed that use of Samsung’s S-Vue™ for pediatric chest images resulted in an overall image quality that was uncompromised even at a significantly reduced radiation exposure,” said Susan John, MD, Professor and Chair, Diagnostic and Interventional Imaging at McGovern Medical School at The University of Texas Health Science Center at Houston (UT Health). “The reduction in radiation dose potentially enables repeat radiographs for better follow-up in patients from infancy into adulthood, while assisting us in confident diagnosis.”

“Constantly working to lower dose exposure is a top priority for radiologists and healthcare professionals, and Samsung’s ability to offer dose reduction across its suite of DR machines represents another breakthrough in medical imaging technology. This new low-dose protocol is proof that we’re continuing to reduce radiation dose in our products. We are delighted that we are now able to offer this to the patients who are most vulnerable,” said David Legg, Vice President, Head of Ultrasound and Digital Radiography Business, at NeuroLogica, the healthcare subsidiary of Samsung Electronics.

Samsung is aiming to lower dose exposure in X-ray systems to push ALARA efforts to the next level for healthcare professionals.

Other FDA News of Interest

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy